Login to Your Account

CMS Cites EPO's Bad Rap In Plan To Curtail Reimbursement

By Aaron Lorenzo

Wednesday, May 16, 2007
Sales of Amgen Inc.'s blockbuster EPO products are facing a further downturn, this time thanks to the Centers for Medicare & Medicaid Services (CMS), and the company's stock on Tuesday lost 3.7 percent as a result. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription